Genfit (GNFT) announced that Ipsen’s Iqirvo has been granted pricing and reimbursement in Italy for Primary Biliary Cholangitis. This step unlocks a new milestone payment of EUR 26.5M under its licensing and collaboration agreement with Ipsen (IPSEY), due upon pricing and reimbursement of Iqirvo in three European markets.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GNFT: